PPARgamma_NN
activation_NN
induces_VBZ
the_DT
expression_NN
of_IN
the_DT
adipocyte_JJ
fatty_JJ
acid_NN
binding_NN
protein_NN
gene_NN
in_IN
human_JJ
monocytes_NNS
._.

The_DT
peroxisome-proliferator_JJ
activated_VBN
receptor_NN
gamma_NN
-LRB-_-LRB-
PPARgamma_NN
-RRB-_-RRB-
,_,
a_DT
member_NN
of_IN
the_DT
nuclear_JJ
receptor_NN
superfamily_NN
of_IN
ligand_JJ
activated_VBN
transcription_NN
factors_NNS
,_,
plays_VBZ
a_DT
key_JJ
role_NN
in_IN
the_DT
anti-diabetic_JJ
actions_NNS
of_IN
the_DT
thiazolidinediones_NNS
-LRB-_-LRB-
TZDs_NNS
-RRB-_-RRB-
._.

PPARgamma_NN
induces_VBZ
the_DT
expression_NN
of_IN
many_JJ
genes_NNS
involved_VBN
in_IN
lipid_NN
anabolism_NN
,_,
including_VBG
the_DT
adipocyte_JJ
fatty_JJ
acid_NN
binding_NN
protein_NN
-LRB-_-LRB-
aP2_NN
-RRB-_-RRB-
,_,
and_CC
is_VBZ
a_DT
key_JJ
regulator_NN
of_IN
adipocyte_NN
differentiation_NN
._.

PPARgamma_NN
is_VBZ
also_RB
expressed_VBN
in_IN
hematopoietic_JJ
cells_NNS
and_CC
is_VBZ
up-regulated_VBN
in_IN
activated_VBN
monocytes\/macrophages_NNS
._.

Activation_NN
of_IN
PPARgamma_NN
may_MD
play_VB
a_DT
role_NN
in_IN
the_DT
induction_NN
of_IN
differentiation_NN
of_IN
macrophages_NNS
to_TO
foam_NN
cells_NNS
that_WDT
are_VBP
associated_VBN
with_IN
atherosclerotic_JJ
lesions_NNS
._.

We_PRP
report_VBP
that_IN
both_CC
natural_JJ
and_CC
synthetic_JJ
PPARgamma_NN
agonists_NNS
induce_VBP
time_NN
-_:
and_CC
dose-dependent_JJ
increases_NNS
in_IN
aP2_NN
mRNA_NN
in_IN
both_CC
primary_JJ
human_JJ
monocytes_NNS
and_CC
the_DT
monocytic_JJ
cell_NN
line_NN
,_,
THP-1_NN
._.

These_DT
data_NNS
suggest_VBP
that_IN
PPARgamma_NN
activation_NN
may_MD
play_VB
a_DT
role_NN
in_IN
monocyte_NN
differentiation_NN
and_CC
function_VB
analogous_JJ
to_TO
its_PRP$
well-characterized_JJ
role_NN
in_IN
adipocytes_NNS
._.

